Potential in retina treatment offered through stem cell research

Article

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight.

A stem cell treatment to replace diseased parts of the retina is being pioneered by scientists funded by the Medical Research Council, the Macular Vision Research Foundation and Fight for Sight. This could lead to a potential treatment for retinal diseases that affect around 3000 children in the UK.

Researchers from the UCL Institute of Child Health and UCL Institute of Ophthalmology as well as members of the UCL Centre for Stem Cells and Regenerative Medicine have successfully implanted cells from healthy mice into those with an inherited form of childhood blindness called Leber Congenital Amaurosis (LCA). The implanted cells, which release a gene, Crx, needed to make healthy cone and rod photoreceptors, integrated with the retina to become new cone photoreceptors. This is the first time this has been achieved. However, more studies are required to show if this method could restore sight.

"We have shown for the first time that it is possible to transplant new cone photoreceptors into the mature retina. The newly-developed cones looked as good as new," asserted Dr Jane Sowden, UCL Institute of Child Health, who led the study. "This is an important step forward as cone photoreceptors are essential for reading and colour vision and loss of this type of cell has the biggest impact on sight."

This study is available in Human Molecular Genetics.

For further information on stem cell technology read the upcoming October issue of Ophthalmology Times Europe for "A primer on the use of stem cells in ophthalmology" by Irving Arons.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.